|
| Title | Journal | Article type | Research contents/drugs | Total citation | Publication year | Page number | PMID |
|
| Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [27] | New England Journal of Medicine | Article | Infliximab | 2689 | 2001 | 6 | 11596589 |
| American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis [28] | American Journal of Respiratory and Critical Care Medicine | Review | Therapeutic monitoring | 1380 | 2003 | 59 | 12588714 |
| The emergence of drug-resistant tuberculosis in New York City [29] | New England Journal of Medicine | Article | Drug-resistant, rifapentine, isoniazid, HIV coinfection | 786 | 1993 | 5 | 8381207 |
| A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis [30] | Nature | Article | Nitroimidazopyran | 772 | 2000 | 4 | 10879539 |
| The challenge of new drug discovery for tuberculosis [31] | Nature | Review | New drugs | 757 | 2011 | 7 | 21270886 |
| Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis [32] | Lancet | Article | Drug resistance | 716 | 2010 | 13 | 20488523 |
| Global surveillance for antituberculosis-drug resistance, 1994-1997 [33] | New England Journal of Medicine | Article | Drug resistance, isoniazid, rifampin, pyrazinamide, ethambutol | 706 | 1998 | 8 | 9614254 |
| An official ATS statement: hepatotoxicity of antituberculosis therapy [34] | American Journal of Respiratory and Critical Care Medicine | Review | Hepatotoxicity | 675 | 2006 | 17 | 17021358 |
| Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin [35] | New England Journal of Medicine | Article | Drug resistance, isoniazid, rifampin | 627 | 1993 | 5 | 8426619 |
| The diarylquinoline TMC207 for multidrug-resistant tuberculosis [10] | New England Journal of Medicine | Article | TMC207, drug-resistant | 590 | 2009 | 8 | 19494215 |
| Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management [36] | Lancet Infectious Diseases | Review | Infliximab, etanercept | 571 | 2003 | 7 | 12614731 |
| Advances in the development of new tuberculosis drugs and treatment regimens [37] | Nature Reviews Drug Discovery | Review | New drug regimen | 567 | 2013 | 16 | 23629506 |
| Drug-therapy - treatment of multidrug-resistant tuberculosis [38] | New England Journal of Medicine | Review | Drug resistance | 555 | 1993 | 7 | 8350889 |
| Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis [39] | American Journal of Respiratory and Critical Care Medicine | Article | Adverse reactions, isoniazid, rifampin, pyrazinamide, ethambutol | 526 | 2003 | 5 | 12569078 |
| Three months of rifapentine and isoniazid for latent tuberculosis infection [40] | New England Journal of Medicine | Article | Latent tuberculosis, rifapentine, isoniazid | 514 | 2011 | 11 | 22150035 |
| The effect of directly observed therapy on the rates of drug-resistance and relapse in tuberculosis [41] | New England Journal of Medicine | Article | Directly observed treatment, drug resistance | 496 | 1994 | 5 | 8139628 |
| Delamanid for multidrug-resistant pulmonary tuberculosis [11] | New England Journal of Medicine | Article | Delamanid (OPC-67683), drug-resistant | 488 | 2012 | 9 | 22670901 |
| Efficacy of various durations of isoniazid preventive therapy for tuberculosis - 5 years of follow-up in the IUAT trial [42] | Bulletin of The World Health Organization | Article | Isoniazid | 484 | 1982 | 9 | 6754120 |
| Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists [43] | Arthritis and Rheumatism | Article | Infliximab, latent tuberculosis | 484 | 2005 | 6 | 15934089 |
| Timing of initiation of antiretroviral drugs during tuberculosis therapy [44] | New England Journal of Medicine | Article, trail | Antiretroviral therapy, HIV coinfection | 483 | 2010 | 9 | 20181971 |
| Literatures on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications [45] | International Journal of Tuberculosis and Lung Disease | Review | Isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin | 476 | 1999 | 48 | 10529902 |
| Standard short-course chemotherapy for drug-resistant tuberculosis - treatment outcomes in 6 countries [46] | JAMA-Journal of the American Medical Association | Article | Drug-resistant, isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin | 465 | 2000 | 8 | 10815117 |
| Treatment of tuberculosis in patients with advanced human-immunodeficiency-virus infection [47] | New England Journal of Medicine | Article | HIV coinfection, isoniazid, rifampin, pyrazinamide, ethambutol | 451 | 1991 | 5 | 1898769 |
| Antituberculosis drugs: ten years of research [48] | Bioorganic & Medicinal Chemistry | Review | New drugs | 439 | 2007 | 34 | 17291770 |
| Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis [49] | American Journal of Respiratory and Critical Care Medicine | Article | Drug-resistant, gatifloxacin, clofazimine, ethambutol, pyrazinamide, prothionamide, kanamycin, isoniazid | 436 | 2010 | 8 | 20442432 |
| High-dose vitamin D-3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial [50] | Lancet | Article | Vitamin D, supplementary | 427 | 2011 | 8 | 21215445 |
| Supplement – American Thoracic Society Centers for Disease Control and Prevention – targeted tuberculin testing and treatment of latent tuberculosis infection [51] | American Journal of Respiratory and Critical Care Medicine | Review | Latent tuberculosis infection, rifampin | 415 | 2000 | 27 | 10764341 |
| Antituberculosis drug-induced hepatotoxicity: concise up-to-date review [52] | Journal of Gastroenterology and Hepatology | Review | Hepatotoxicity, first-line drugs | 410 | 2008 | 11 | 17995946 |
| Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998 [53] | Thorax | Review | Guidelines on chemotherapy | 409 | 1998 | 12 | 9797751 |
| Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients [54] | Plos Medicine | Review | Drug-resistant, fluoroquinolones, ethionamide, prothionamide | 407 | 2012 | 0 | 22952439 |
| Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis [55] | Lancet Infectious Diseases | Review | Drug-resistant, treatment regimens | 406 | 2009 | 8 | 19246019 |
| WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update [56] | European Respiratory Journal | Article | Guidelines, drug-resistant | 405 | 2011 | 12 | 21828024 |
| Timing of antiretroviral therapy for HIV-1 infection and tuberculosis [57] | New England Journal of Medicine | Article | Antiretroviral therapy, HIV coinfection | 403 | 2011 | 9 | 22010914 |
| The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis [58] | American Journal of Respiratory and Critical Care Medicine | Article | Nanoparticle-based drug delivery systems | 403 | 2005 | 4 | 16151040 |
| Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV-infection [59] | Lancet | Article | Isoniazid, HIV coinfection | 397 | 1993 | 4 | 8101302 |
| Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru [60] | New England Journal of Medicine | Article | Drug-resistant, pyrazinamide, ethambutol | 392 | 2003 | 9 | 12519922 |
| Multidrug-resistant tuberculosis and culture conversion with bedaquiline [61] | New England Journal of Medicine | Article | Bedaquiline (Sirturo, TMC207), drug-resistant | 387 | 2014 | 10 | 25140958 |
| Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis [62] | Lancet Infectious Diseases | Article | Drug-resistant, multiple drugs | 379 | 2010 | 9 | 20797644 |
| Linezolid for treatment of chronic extensively drug-resistant tuberculosis [63] | New England Journal of Medicine | Article | Linezolid, drug-resistant | 365 | 2012 | 11 | 23075177 |
| Integration of antiretroviral therapy with tuberculosis treatment [64] | New England Journal of Medicine | Article | Integrating antiretroviral therapy, HIV coinfection | 358 | 2011 | 10 | 22010915 |
| Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d’Ivoire: a randomised controlled trial [65] | Lancet | Article | Trimethoprim-sulphamethoxazole, HIV coinfection | 355 | 1999 | 7 | 10232312 |
| Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis [66] | New England Journal of Medicine | Article | Moxifloxacin, isoniazid, rifampin, pyrazinamide, ethambutol | 355 | 2014 | 11 | 25196020 |
| Toxic hepatitis with isoniazid and rifampin – a meta-analysis [67] | Chest | Review | Hepatotoxicity, isoniazid, rifampin | 344 | 1991 | 7 | 1824929 |
| Prospects for worldwide tuberculosis control under the WHO DOTS strategy [68] | Lancet | Article | Short-course drug regimen, HIV coinfection | 342 | 1998 | 6 | 9863786 |
| Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis [69] | Hepatology | Article | Hepatotoxicity, isoniazid, genotyped NAT2 | 337 | 2002 | 7 | 11915035 |
| A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus [70] | New England Journal of Medicine | Article | First-line drugs, HIV coinfection | 336 | 1997 | 8 | 9295239 |
| Hepatotoxicity associated with isoniazid preventive therapy – a 7-year survey from a public health tuberculosis clinic [71] | JAMA-Journal of the American Medical Association | Article | Isoniazid, hepatotoxicity | 336 | 1999 | 5 | 10086436 |
| The magic bullets and tuberculosis drug targets [72] | Annual Review of Pharmacology and Toxicology | Review; book chapter | Chemotherapy review | 322 | 2005 | 36 | 15822188 |
| Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial [73] | Lancet | Article | Rifapentine, isoniazid | 318 | 2002 | 7 | 12241657 |
| Vitamin D as supplementary treatment for tuberculosis a double-blind, randomized, placebo-controlled trial [74] | American Journal of Respiratory and Critical Care Medicine | Article | Vitamin D, supplementary | 308 | 2009 | 8 | 19179490 |
|
